CoChat

Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis

Open access
Bowlus, Christopher L., Pockros, Paul J., Kremer, Andreas E., Parés, Albert, Forman, Lisa M., Drenth, Joost P.H., Ryder, Stephen D., Terracciano, Luigi, Jin, Yuying, Liberman, Alexander, Pencek, Richard, Iloeje, Uche, MacConell, Leigh, Bedossa, Pierre · 2020 · Clinical Gastroenterology and Hepatology
Cited by 105

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS Primary biliary cholangitis (PBC) is an auto-immune disease characterized by bile duct destruction that can progress to cirrhosis. A liver biopsy substudy was conducted in the PBC obeticholic acid (OCA) international study of efficacy (POISE) to determine the long-term effects of OCA on liver damage and fibrosis in patients with PBC. POISE is a phase 3, double-blind, placebo-controlled, randomized trial with a 5-year open-label extension that evaluated daily OCA 5 to 10 mg in patients who were intolerant or unresponsive to ursodeoxycholic acid. METHODS Liver biopsies were collected from 17 patients at time of enrollment in the double-blind phase and after 3 years of OCA treatment. Histological evaluations were performed by 2 pathologists in a blinded, randomized fashion to determine the effects of OCA on fibrosis and other histological parameters. Collagen morphometry assessments were performed by automated second harmonic generation and 2-photon excitation microscopy to observe quantitative measures of fibrosis. RESULTS From time of enrollment until 3 years of treatment, most patients had improvements or stabilization in fibrosis (71%), bile duct loss (76%), ductopenia (82%), ductular reaction (82%), interface hepatitis (100%), and lobular hepatitis (94%). Over the 3-year period, we found significant reductions in collagen area ratio (median -2.1; first quartile, -4.6 and third quartile, -0.3 ; P = .013), collagen fiber density (median -0.8; first quartile, -2.5 and third quartile, 0; P = .021), collagen reticulation index (median -0.1; first quartile -0.3 and third quartile, 0; P = .008), and fibrosis composite score (median -1.0; first quartile, -2.5 and third quartile, -0.5; P = .002). CONCLUSIONS A sub-analysis of data from the POISE study demonstrated that long-term OCA treatment in patients with PBC is associated with improvements or stabilization of disease features, including ductular injury, fibrosis, and collagen morphometry features (ClinicalTrials.gov no: NCT01473524 and EudraCT no: 2011-004728-36).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2019.09.050

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 105

Metadata

Authors
Bowlus, C. L., Pockros, P. J., Kremer, A. E., Parés, A., Forman, L. M., Drenth, J. P. H., Ryder, S. D., Terracciano, L., Jin, Y., Liberman, A., Pencek, R., Iloeje, U., MacConell, L., & Bedossa, P.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2020-05
Volume
18
Issue
5
Pages
1170-1178.e6
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2979836537
Cited by
105
References
19
FWCI
6.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. https://app.cochat.ai/papers/10.1016/j.cgh.2019.09.050
The paper
Bowlus, C. L., Pockros, P. J., Kremer, A. E., Parés, A., Forman, L. M., Drenth, J. P. H., Ryder, S. D., Terracciano, L., Jin, Y., Liberman, A., Pencek, R., Iloeje, U., MacConell, L., & Bedossa, P. (2020). Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2019.09.050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.